AI Article Synopsis

  • Focal atrial tachycardia (FAT) is an organized fast heart rhythm that originates from a specific spot in the atria, with the potential for it to be persistent or come and go.
  • A case study discusses a 36-year-old man who experienced symptoms like palpitations and was initially misdiagnosed with atrial flutter, but was later correctly diagnosed with FAT and underwent successful ablation.
  • Distinguishing between FAT and atrial flutter is essential for effective treatment, which can be done by analyzing differences in ECG patterns, such as wave shapes and intervals.

Article Abstract

Focal atrial tachycardia (FAT) is an organized atrial rhythm >100 beats per minute initiated from a discrete origin and spreading over both atria in a centrifugal pattern. The arrhythmia may be sustained or incessant. Dynamic forms with recurrent interruptions and reinitiating may be frequent. In this report, we present a 36-year-old man who came to the emergency room complaining of palpitation and shortness of breath. All laboratory evaluations were normal. With an initial electrocardiogram (ECG) the patient was admitted with the initial diagnosis of atrial flutter. Finally, after the electrophysiologist's examination, with the diagnosis of FAT, ablation was successfully performed. Atrial tachycardia (AT), excluding atrial fibrillation (AF) and cavotricuspid isthmus-dependent atrial flutter (AFL), account for 10% of supraventricular tachycardia referred for ablation procedures. More than 70% of these cases are focal and occur in patients with no records of cardiac surgery or ablation of AF. FAT originating from the right pulmonary veins (PV) can be challenging to differentiate from atrial flutter due to their proximity and overlapping symptoms. The right PV is close to the right atrium, and the abnormal electrical activity in FAT may mimic the organized circuit found in atrial flutter. Distinguishing between FAT and atrial flutter is crucial for choosing the best therapeutic option. This can be done most of the time by focusing on the differences in the pattern of their P and QRS waves, R-R wave intervals, and also their baseline changes on ECG, as well as their cycle duration, response to adenosine and risk factors of the patient.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10974688PMC
http://dx.doi.org/10.1002/ccr3.8689DOI Listing

Publication Analysis

Top Keywords

atrial flutter
20
atrial tachycardia
12
atrial
11
focal atrial
8
fat
5
flutter
5
navigating fine
4
fine focal
4
tachycardia
4
tachycardia atrial
4

Similar Publications

Population Pharmacokinetics and Pharmacodynamics of Sotalol Following Expedited Intravenous Loading in Patients With Atrial Arrhythmias.

CPT Pharmacometrics Syst Pharmacol

January 2025

Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA.

Sotalol, a class III antiarrhythmic agent, is used to maintain sinus rhythm in patients with atrial fibrillation or atrial flutter (AFIB/AFL). Despite its efficacy, sotalol's use is limited by its potential to cause life-threatening ventricular arrhythmias due to QT interval prolongation. Traditionally, sotalol administration required hospitalization to monitor these risks.

View Article and Find Full Text PDF

Background: Atrial flutter (AFL) is usually effectively treated by cavotricuspid isthmus (CTI) ablation. If AFL recurs despite ablation, there is risk of progression to atrial fibrillation (AF) and clinicians should consider underlying structural heart diseases. This consideration becomes especially critical when right-heart-chambers are dilated.

View Article and Find Full Text PDF

Association between autoimmune diseases and all-cause mortality in patients with cardiac arrhythmia.

Rev Esp Cardiol (Engl Ed)

December 2024

Arrhythmia Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. Electronic address:

Article Synopsis
  • Autoimmune diseases (ADs) are linked to a higher risk of all-cause mortality in patients with cardiac arrhythmias, particularly atrial fibrillation and ventricular tachycardia.
  • The study analyzed data from over 14,000 patients, finding that those with ADs had increased mortality rates after one year of discharge.
  • Statistical analyses confirmed these results, highlighting the significant risk associated with ADs in arrhythmia patients, although the association for bradyarrhythmias did not reach statistical significance.
View Article and Find Full Text PDF

Comparing pulsed field ablation with very high-power and high-power short-duration radiofrequency ablation for atrial fibrillation: a systematic review and meta-analysis.

J Interv Card Electrophysiol

December 2024

Section of Electrophysiology, Division of Cardiology, Department of Medicine, Rush University Medical Center, 1717 W Congress Pkwy/Suite 317 Kellogg, Chicago, IL, 60612, USA.

Background: Catheter ablation is a key treatment for atrial fibrillation (AF), with high-power, very high-power short-duration and pulsed field ablation (PFA) being efficient options. However, direct comparisons between these techniques are lacking.

Objective: We performed a systematic review and meta-analysis, which included predominantly observational studies (four retrospective and one prospective study), to compare PFA and High-power short-duration (HPSD) and very high-power short-duration (vHPSD) radiofrequency (RF) ablation in patients with AF.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!